Marvel Biosciences to Host Investor Webinar

Calgary, Alberta–(Newsfile Corp. – November 29, 2021) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively theCompany or Marvel“), is pleased to announce that it will host an investor webinar via Zoom on Wednesday, December 1, 2021 at 1:00pm EST. The presentation will feature President and Chief Scientific Officer Mark Williams, who will walk through the investor presentation and provide an update on the business. A question and answer session will follow.

To register for the investor webinar, please click here or visit https://bit.ly/MRVLPresentation.

About Marvel Biosciences Corp.

Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a “drug redevelopment” approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.

Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer’s, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis (“NASH”). Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

Contact Information

Investor Relations: 
Virtus Advisory Group
Tel: 416-644-5081
Email: info@virtusadvisory.com

Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469
Email: info@marvelbiosciences.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

All information contained in this news release with respect to the Company and its subsidiary, (collectively, the “Parties”) were supplied by Marvel, respectively, for inclusion herein and each parties’ directors and officers have relied on each other for any information concerning such Party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

Marvel Biosciences Lead Asset MB-204 Show 47% Reduction in Liver Fibrosis and Active Indications in Multiple Pre-Clinical Models of Nash

Calgary, Alberta–(Newsfile Corp. – November 23, 2021) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the Company or Marvel“), today announced that it has found its lead asset, MB-204 was active in two different pre-clinical models of non-alcoholic steatohepatitis (“NASH”) using fibrosis and the non-alcoholic fatty liver disease activity score (NAS score) endpoints that are analogous to the known approvable NASH endpoints with the FDA. These early indications highlight a promising trajectory for MB-204 as a prospective treatment for NASH disease.

NASH is a global disease that affects a significant portion of the population with a global market representing over $20B USD. The major concern for physicians and their patients is the development of liver fibrosis which can result in cirrhosis and liver cancer. Currently, there are no approved treatments for NASH, and very few treatments in development are focused on reduction in fibrosis. The most advanced active candidate specifically targeting fibrosis is Cenicriviroc which is currently in Phase 3 clinical trials.

The Company studied its lead adenosine A2a receptor antagonist MB-204 in two pre-clinical NASH models and concluded the following:

  • In the first model, focusing on the NAS Score, 6-week old STAM® mice (SMC, Japan) were treated with MB-204 (10 mg/kg), once daily per oral for 3 weeks. A 1.4 point drop in the NAS score (p<0.01) was observed, with a particularly strong effect seen on hepatocyte ballooning (p<0.0001) compared to vehicle.
  • In the second model, focusing on fibrosis, 30-week old pre-aged NASH mice (Taconic) were treated once daily per oral for approximately 3 weeks with MB-204 (10mg/kg) or Cenicriviroc (30 mg/kg), the leading anti-fibrotic treatment for NASH in Phase 3 clinical trials. A 47% reduction in fibrosis was observed comparing control and MB-204, and MB-204 was significantly better (p<0.05) compared to Cenicriviroc in this experiment.

Bruce N. Cronstein, MD and Marvel Scientific Advisory Board advisor stated, “This is encouraging for the NASH treatment space and is not surprising as our laboratory was the first group to link the adenosine A2a receptor to liver fibrosis over 20 years ago. Current thinking is that A2a antagonism, at least in part, likely prevents activation of hepatic stellate cells, the cells that produce collagen and fibrosis in the liver. Fibrosis is a central concern for physicians when a patient presents with NASH as it is highly associated with the development of liver dysfunction, cirrhosis, cancer and death.”

“We are pleased with these further MB-204 results as we believe it could represent a first-in-class treatment for the disease and further de-risks our asset by having a second, non-neurological disease we can pursue,” said Dr. Mark Williams, President and Chief Science Officer. “Early indications show promising signs for the future of our lead candidate, with next steps including continuing additional pre-clinical trial and ultimately moving towards a Phase 1 study. We are extremely excited about the opportunity that exists with MB-204 and believe this could become a viable and standard treatment for NASH disease in the future.”

MB-204, is a fluorinated derivative developed by Marvel of the US-FDA approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world, whose consumption has been associated with a reduced risk for developing Parkinson’s disease, Alzheimer’s disease and improving concentration.

About Professor Bruce N. Cronstein, MD

Professor Bruce N. Cronstein, MD, is a Professor at the NYU Grossman School of Medicine (for the Departments of Medicine, Pharmacology, and Pathology). Prof. Cronstein is considered the world expert on adenosine, and has led adenosine research for over 38 years, publishing a monumental 365 peer-reviewed articles. The Cronstein laboratory has explored the role of adenosine across multiple thematic areas (including studying its application in neutrophils, inflammation, methotrexate treatments, and since the early 2000s, the adenosine A2A receptor). Prof. Cronstein has led the research of A2A receptor functions, including its roles in dermal fibrosis and scarring, hepatic fibrosis and fatty liver, bone healing, and more recently, chondrocyte metabolism and cartilage matrix maintenance. Prof. Cronstein’s discoveries have led to novel therapeutics and treatments now considered best practice.

About Marvel Biosciences Corp.

Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a “drug redevelopment” approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.

Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer’s, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis (“NASH”). Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

Contact Information

Investor Relations:
Virtus Advisory Group
Tel: 416-644-5081
Email: info@virtusadvisory.com

Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer or  Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469
Email: info@marvelbiosciences.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

All information contained in this news release with respect to the Company and its subsidiary, (collectively, the “Parties”) were supplied by Marvel, respectively, for inclusion herein and each parties’ directors and officers have relied on each other for any information concerning such Party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

Marvel Biosciences Announces New Program to Develop Novel Orally Dosed Non-Hallucinogenic Neuroplastic Promoting Compounds

Calgary, Alberta–(Newsfile Corp. – October 27, 2021) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the Company or Marvel“), is pleased to announce that the Company has initiated a new program whose goal is to identify and develop novel, safe agents that promote neuroplasticity without the liabilities of abuse potential or hallucinations that occur with psychedelics which include ketamine, LSD and tryptamine derivatives such as DMT and psilocybin.

Marvel has identified a series of compounds inspired by known psychedelic molecules, that appear to be active as anti-depressants in pre-clinical testing. The compounds were administered for seven days, and preliminary evidence found multiple molecules with the same core structure capable of reducing depressive symptoms as measured in the widely accepted forced swim test. Early indications are extremely positive, with the swim test producing 2 positive indicators that exhibited strong potential for treatment.

Key features of the first class of molecules that Marvel has developed are:

  • fast acting
  • orally available
  • water soluble
  • no evidence of hallucinatory activity
  • significantly better (p<0.05) than fluoxetine (Prozac)

“Although early, this is an auspicious start for our new program that presents a compelling opportunity, as we further expand our product portfolio,” commented Dr. Mark Williams, President and Chief Science Officer. “We need to further characterize and expand upon the first set of hits we have identified, and we are also investigating molecules with very different structures to the known psychedelics to promote neuroplasticity as well. We are strong advocates for the use of psychedelic treatments to address mental health issues, yet it is critical that they are put through rigorous testing to ensure efficacy and safety for patients.”

“This program is in addition to our current development program of our caffeine inspired lead compound asset MB-204 being developed for neurological conditions such as depression and anxiety, Alzheimer’s disease (AD) and ADHD. MB-204 is in the manufacturing development phase and advancing well towards the clinic,” stated Rod Matheson, Chief Executive Officer. “We look forward to advancing this new program quickly owing to the potential breadth of neuroplastic agents to treat not only depression but PTSD, AD, Parkinson’s disease, autism, ALS, fetal alcohol exposure and schizophrenia for example.”

About Marvel Biosciences Corp.

Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a “drug redevelopment” approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.

Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer’s, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

Contact Information

Investor Relations:
Virtus Advisory Group
Tel: 416-644-5081
Email: info@virtusadvisory.com

Marvel Biosciences Corp.
Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469
Email: info@marvelbiotechnology.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

All information contained in this news release with respect to the Company and its subsidiary, (collectively, the “Parties”) were supplied by Marvel, respectively, for inclusion herein and each parties’ directors and officers have relied on each other for any information concerning such Party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

Marvel Biosciences Provides Updates on the Status of Its MB-204 Manufacturing Efforts and Sets Out Future Milestones

Calgary, Alberta–(Newsfile Corp. – October 15, 2021) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc.(collectively the”Company“or”Marvel“), is pleased to announce that as a result of successful process development of the active pharmaceutical ingredient (“API”) of its lead drug MB-204, the Company has now entered an important milestone of engineering and subsequent current good manufacturing practices (“cGMP”) run of its multi-kilogram batches of MB-204 in partnership with Zhejiang Ausun Pharmaceutical Co., Ltd. (“Ausun”).

The engineering run will provide the Company with a batch of its lead drug candidate MB-204 that can be used in good laboratory practice (“GLP”) toxicology studies, which are scheduled to begin in Q4 2021. Ausun will also be providing the Company with a cGMP batch of MB-204 that ensures identity, quality and purity in preparation of entering Phase I clinical studies in 2022 following the completion of the Company’s toxicology studies.

“To date we have shown in a number of pre-clinical studies the level of efficacy and safety MB-204 can deliver,” said Rod Matheson, Chief executive Officer of Marvel. “With the partnership we have in place with Ausun, we have now entered a key and very important stage in the development of MB-204 to drive this asset into clinical studies. These milestones are key in further advancing our discussions with potential commercial partners to ensure the best outcome for our shareholders.”

Marvel’s lead compound asset MB-204 (“MB-204”) is being developed for neurological conditions such as depression and anxiety, Alzheimer’s and ADHD. Marvel’s compound is a novel patented fluorinated derivative of the US-FDA approved Parkinson’s disease drug Istradefylline (Nourianz®). Both Istradefylline and MB-204 are highly active derivatives of caffeine, which act as antagonists of the adenosine A2a receptor (“A2aR”). Caffeine is the most widely consumed psychoactive drug in the world and has been associated with a reduced risk for developing Parkinson’s disease, Alzheimer’s disease and improving concentration.

The upcoming Company milestones for its lead compound asset MB-204 include:

  • Completion of 2 kg of engineering run material in Q4 2021;
  • Initiation of IND-enabling toxicology studies in Q4 2021;
  • Completion of 2 kg of cGMP API in Q1 2022;
  • Completion of GLP toxicology expected Q2 2022; and
  • Initiation of Phase 1 with potential efficacy endpoints in Q3 2022.

About Marvel Biosciences Corp.

Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a “drug redevelopment” approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.

Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer’s, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

Contact Information

Investor Relations:
Virtus Advisory Group
Tel: 416-644-5081

Email: info@virtusadvisory.com 

Marvel Biosciences Corp.
Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469

Email: info@marvelbiotechnology.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

All information contained in this news release with respect to the Company and its subsidiary, (collectively, the “Parties”) were supplied by Marvel, respectively, for inclusion herein and each parties’ directors and officers have relied on each other for any information concerning such Party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

Marvel Biosciences Corp. to Present at the 22nd International Conference on Alzheimer’s Drug Discovery

Calgary, Alberta–(Newsfile Corp. – September 17, 2021) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc.(collectively the”Company“or”Marvel“), is pleased to announce that it has been accepted to present at the start-up company forum at the 22nd International Conference of Alzheimer’s Drug Discovery, a virtual conference on October 4 and 5th, 2021 hosted by the Alzheimer’s Drug Discovery Foundation.

The 2020 conference attracted close to 900 attendees from around the world. Attendees included: academic and industry scientists, business development and licensing professionals, venture capitalists and other investors.

“Our pre-clinical data to date has shown great promise in terms of efficacy and safety of our lead compound MB-204,” said Dr. Mark Williams, President and Chief Science Officer, who will be giving the presentation. “Establishing strategic R&D and commercialization partnership is key to our overall business strategy, and an opportunity to increase visibility among industry leaders as we actively move our lead compound through key developmental milestones is fundamental to our business.”

Marvel’s lead compound asset MB-204 is being developed for neurological conditions such as depression and anxiety, Alzheimer’s and ADHD. Marvel’s compound is a novel patented fluorinated derivative of the US-FDA approved Parkinson’s disease drug Istradefylline (Nourianz®). Both Istradefylline and MB-204 are highly active derivatives of caffeine, which act as antagonists of the adenosine A2a receptor (“A2aR”). Caffeine is the most widely consumed psychoactive drug in the world and has been associated with a reduced risk for developing Parkinson’s disease, Alzheimer’s disease and improving concentration.

About Marvel Biosciences Corp.

Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a “drug redevelopment” approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.

Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer’s, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

Contact Information

Investor Relations: 
Virtus Advisory Group
Tel: 416-644-5081

Email: info@virtusadvisory.com

Marvel Biosciences Corp.
Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469

Email: info@marvelbiotechnology.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

All information contained in this news release with respect to the Company and its subsidiary, (collectively, the “Parties”) were supplied by Marvel, respectively, for inclusion herein and each parties’ directors and officers have relied on each other for any information concerning such Party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

Marvel Biosciences Corp. Updates Market on Its Lead Caffeine Inspired Asset MB-204 for Neurological Diseases

Calgary, Alberta–(Newsfile Corp. – August 5, 2021) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the Company or Marvel“), is pleased to provide an update on its lead compound asset MB-204 (“MB-204”) being developed for neurological conditions such as depression and anxiety, Alzheimer’s and ADHD. Marvel’s compound is a novel patented fluorinated derivative of the US-FDA approved Parkinson’s disease drug Istradefylline (Nourianz®). Both Istradefylline and MB-204 are highly active derivatives of caffeine, which act as antagonists of the adenosine A2a receptor (“A2aR”). Caffeine is the most widely consumed psychoactive drug in the world and has been associated with a reduced risk for developing Parkinson’s disease, Alzheimer’s disease and improving concentration.

The Company has observed the following key pre-clinical properties of its lead asset MB-204:

  • The compound is an antagonist of A2aR with a consistently similar in vitro IC50 as Istradefylline (75 vs 67 nM respectively);
  • The compound has a very favourable oral pharmacokinetic profile in mice with a higher bioavailability (56% vs 30.9%) and longer half life than Istradefylline (2.9 vs 2.2 hours), the latter property confirmed by in vivo brain receptor occupancy studies (p<0.01);
  • Demonstrated a clear dose dependent reduction in immobility time (p<0.0001) in a forced swim test model of depression at doses that did not trigger an increase in general locomotive activity;
  • In a head-to-head study with Istradefylline conducted in an elevated plus model of anxiety, MB-204 exhibited a superior anti-anxiety profile;
  • A slightly better toxicity profile (lower liver enzymes, ALT and AST) and lower creatinine levels than Istradefylline in a sub-chronic dosing experiment.

This data in totality suggests MB-204 could be dosed as a once-a-day oral agent, possessing an attractive profile for central nervous system (“CNS”) diseases involving A2aR.

“We based our molecule MB-204 off Istradefylline, the only US-FDA clinically approved A2aR antagonist, making logical changes to the original molecule to retain activity, but improve other qualities such as oral bioavailability” said Dr. Mark Williams, President and Chief Scientific Officer of Marvel. “The results we have received so far in our pre-clinical studies are highly encouraging and gives us a high degree of confidence in potential applications of MB-204 in helping a growing number of patients suffering from neurological diseases, such as depression and Alzheimer’s disease. In our studies we saw that not only did our compound bind to the right target in the brain, the A2aR receptor, but a high concentration of it was able to enter the brain upon oral consumption and its effect lasted longer than Istradefylline.”

“Our goal is to develop an asset that may have multiple applications,” said Rod Matheson, Chief Executive Officer of Marvel. “We like to describe MB-204 as a ‘pipeline in a product’ as it may have more than one central nervous system indication, and it may also have applications outside neurological diseases such as non-alcoholic steatohepatitis (“NASH”) and cancer. We believe by having more than one, unrelated disease MB-204 can go after, the Company de-risks the development of this asset.”

Marvel previously announced on July 21, 2021 that the Company had entered into a current good manufacturing process (cGMP) manufacturing agreement with Zhejiang Ausun Pharmaceutical Co., Ltd. (“Ausun”) for the supply of its lead asset MB-204 for GLP pre-clinical toxicology studies and clinical trials.

About Marvel Biosciences Corp.

Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based biotechnology company that utilizes a “drug redevelopment” approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.

Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer’s, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

Contact Information

Investor Relations: 
Virtus Advisory Group
Tel: 416-644-5081

Email: info@virtusadvisory.com

Marvel Biosciences Corp.
Dr. Mark Williams, President and Chief Science Officer
Tel: 403-770-2469

Email: info@marvelbiotechnology.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

All information contained in this news release with respect to the Company and its subsidiary, (collectively, the “Parties”) were supplied by Marvel, respectively, for inclusion herein and each parties’ directors and officers have relied on each other for any information concerning such Party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

MARVEL BIOSCIENCES CORP. RETAINS VIRTUS ADVISORY GROUP TO PROVIDE CORPORATE COMMUNICATIONS SERVICES

2021-08-03 17:38 ET – News Release

 

Mr. J. Roderick (Rod) Matheson reports

MARVEL BIOSCIENCES CORP. RETAINS VIRTUS ADVISORY GROUP TO PROVIDE CORPORATE COMMUNICATIONS SERVICES

Marvel Biosciences Corp. has retained Virtus Advisory Group Inc. to develop and implement a strategic corporate communications program to increase the company’s exposure among industry stakeholders and investors across Canada.

In connection with the engagement, Virtus has been awarded a consulting contract that includes a monthly fee of $7,000 and a grant of incentive stock options, which will vest in equal instalments over a 12-month period, to acquire 400,000 common shares of the company, exercisable at a price of 40 cents per share for a period of five years from date of grant. The 400,000 incentive stock options are subject to board of director approval, regulatory approval and policies as applicable by the TSX Venture Exchange, and may only vest and be exercised after disinterested shareholder approval of the company’s stock option plan at the next shareholders meeting held by the company.

About Virtus Advisory Group

Virtus is a Toronto-based consulting firm, providing select private and publicly listed companies with business consulting, capital markets strategy and investor relations services. The company provides expert counsel and access to an unmatched network of investors and capital markets professional across Canada and the United States. Virtus helps issuers establish the relationships and the investor confidence required to build long-term shareholder value.

About Marvel Biosciences Corp.

Marvel Biosciences, and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based biotechnology company that utilizes a drug redevelopment approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified that involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought as the new potential asset is developed by the company. The company believes the business model results in significantly less risk, cost and time to develop its assets compared with traditional biotechnology companies.

Marvel Biotechnology has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer’s, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel Biotechnology is also exploring additional undisclosed targets to expand its asset pipeline.

We seek Safe Harbor.

© 2021 Canjex Publishing Ltd. All rights reserved.

MARVEL BIOSCIENCES CORP. TO COMMENCE CGMP MANUFACTURING OF ITS LEAD ASSET MB-204

2021-07-21 12:37 ET – News Release

Dr. Mark Williams reports

MARVEL BIOSCIENCES CORP. TO COMMENCE CGMP MANUFACTURING OF ITS LEAD ASSET MB-204

Marvel Biosciences Corp.’s wholly owned subsidiary Marvel Biotechnology Inc. has achieved a significant science milestone in the development of its lead compound MB-204. Marvel Biotechnology has entered into a current good manufacturing process (cGMP) manufacturing agreement with Zhejiang Ausun Pharmaceutical Co., Ltd. (Ausun) for the supply of its lead asset MB-204 for toxicology studies and clinical trials. MB-204 is the company’s lead compound with potential application to the neurological diseases of depression and anxiety, Alzheimer’s, ADHD (attention-deficit/hyperactivity disorder) and non-neurological diseases such as cancer and non-alcoholic steatohepatitis.

Ausun was chosen and the agreement entered into as a result of an extensive request for proposal (RFP) process and negotiations undertaken by Marvel Biotechnology for the pilot manufacturing of its lead compound, MB-204. The company believes that Ausun possesses the expertise in process development and custom manufacturing of active pharmaceutical ingredients, intermediates and formulated products, and will develop the chemical process and manufacture of Marvel’s MB-204 active pharmaceutical ingredient (API) formulation.

“This is a major science milestone event for the company as we work to achieve and develop our lead asset MB-204 for clinical testing and commercialization,” stated Dr. Mark Williams, president and chief science officer of Marvel. “This program has now commenced and follows after the completion of our reverse takeover and amalgamation transaction with our partners at Alphanco, and the recommencement of trading on the TSX-V last week as Marvel Biosciences Corp. We look forward to updating the market on our progress and the lead asset MB-204.”

About Marvel Biosciences Corp.

Marvel Biosciences, and its wholly owned subsidiary Marvel Biotechnology Inc., is a Calgary-based biotechnology company that utilizes a drug redevelopment approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target but typically only approved for a specific disease. Often, a new disease is identified which involves the same target; however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought as the new potential asset is developed by the company. The company believes the business model results in significantly less risk, cost and time to develop its assets compared with traditional biotechnology companies.

Marvel Biotechnology has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer’s, ADHD) and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

We seek Safe Harbor.

© 2021 Canjex Publishing Ltd. All rights reserved.

ALPHANCO VENTURE CORP. CHANGES NAME TO MARVEL BIOSCIENCES CORP. AND COMPLETES ACQUISITION OF MARVEL BIOTECHNOLOGY INC.

Calgary, Alberta, July 8, 2021 – Alphanco Venture Corp. (TSX-V: AVC.P) (the“Company”or“AVC”), a capital pool company listed on the TSX Venture Exchange (the “TSXV”), is pleased to announce that it has closed its proposed “Qualifying Transaction”, as defined under TSXV policies, being the acquisition of all of the outstanding shares (the “Transaction”) of Marvel Biotechnology Inc. (“Marvel Biotech”) effective June 14, 2021. In connection with closing of the Qualifying Transaction, AVC has changed its name to Marvel Biosciences Corp.

The arm’s length acquisition of Marvel Biotech was structured as a three-cornered amalgamation, whereby AVC acquired all of the issued and outstanding shares of Marvel Biotech through an amalgamation between a wholly owned subsidiary of AVC and Marvel Biotech. The amalgamation resulted in the shareholders of Marvel Biotech receiving common shares of AVC (the “Common Shares”) as consideration under the amalgamation and Marvel Biotech becoming a wholly-owned subsidiary of the Company.  The Transaction is classified as a reverse take-over.

Final approval of the Transaction will occur upon the issuance of the Final Exchange Bulletin (the “Bulletin”) by the TSXV. Subject to final acceptance by the TSXV, the Common Shares of Marvel Biosciences Corp. are expected to commence trading on the TSXV under the symbol “MRVL on or about July 12, 2021, and the Company will be classified as a Tier 2 life sciences issuer pursuant to TSXV policies.

Shareholders of the Company are not required to take any action with respect to the name change and are not required to exchange any existing certificates bearing the Company’s old name. The Company’s transfer agent and registrar, Odyssey Trust Company, will send registered shareholders a new Direct Registration System statement representing the number of Common Shares held by such shareholders.

A copy of the Company’s press releases and TSXV Filing Statement, which contains comprehensive disclosure on the Transaction and the business of the Company and Marvel Biotech, has been filed on SEDAR under the Company’s profile at www.SEDAR.com .

Private Placement Financing Conditions to Final TSXV Acceptance

As part of the TSXV conditional approval of the Transaction and issuance of the Bulletin, the Company was required to complete a private placement financing (the “Financing’) of a minimum of 6,400,000 Common Shares of the Company at a price of $0.40 per share for proceeds of $2,560,000.  On June 10, 2021, the Company completed the Financing for gross proceeds of $2,616,000 through the issuance of 6,540,000 Common Shares at $0.40 per share. A cash finder’s fee of $144,000 was paid to eligible finders in connection with the Financing.

All securities issued in connection with the Financing are subject to a statutory hold period of four months plus a day, expiring October 11, 2021 in accordance with applicable securities legislation.

Proceeds from the Offering will be used for Company operations and in support of the cGMP synthesis and GLP toxicology studies of its lead asset, MB-204 with application to neurological diseases (depression & anxiety, Alzheimer’s, ADHD and addiction), cancer, and application to the non-neurological disease of non-alcoholic steatohepatitis liver fibrosis. Proceeds will also be used for further research on MB-204 and additional potential pipeline products in development or to be identified as a result of internal research; and for general working capital purposes.

Additional information on the Company

In connection with the Transaction, Marvel Biosciences Corp. board of directors has been reconstituted and is now comprised of the following individuals: 

Joanne Yan

Neil A Johnson

Jeremy Fehr

J. Roderick (Rod) Matheson – Chief Executive Officer

Dr. Mark Williams – President and Chief Science Officer

In addition, the Company has appointed Preston J. Maddin as Chief Financial Officer and Jacqueline Groot as Corporate Secretary.

Capital Structure

Upon issuance of the Bulletin, including the Financing, the issued and outstanding share capital of the Company consists of 32,586,231 Common Shares, including 6,540,000 Common Shares issued pursuant to the Financing. The Company will also have 10,071,533 warrants outstanding at various dates of maturity up to April 30, 2023.

A total of 14,250,098 Common Shares will be subject to escrow agreements, including 2,700,000 Common Shares originally issued to the Company’s principals upon listing the Company as a “capital pool company” (the “CPC Escrow Shares“), and 11,400,098 Common Shares issued to principals in connection with the Transaction (the “Value Escrow Shares“). 25% of the CPC Escrow Shares will be released from escrow upon issuance of the Bulletin, with an additional 25% every six months thereafter. 10% of the Value Escrow Shares will be released upon issuance of the Bulletin and 15% every six months thereafter.

A total of 1,775,000 warrants are subject to a Tier 2 value escrow and will be released from escrow on the same terms as the Value Escrow Shares.

“We are pleased to announce the completion of this significant milestone for our Company and with our partners at Alphanco”, stated Rod Matheson, CEO of Marvel Biotech. “This financing will allow Marvel Biotech to develop its lead asset MB-204 for clinical testing. We look forward to updating the market on our progress and MB-204 with application to the neurological diseases of depression & anxiety, Alzheimer’s, ADHD and addiction, cancer, and the application to the non-neurological disease of non-alcoholic steatohepatitis liver fibrosis.”

About Marvel Biotechnology Inc.

Marvel Biotechnology Inc., a wholly owned subsidiary of Marvel Biosciences Corp., is a Calgary-based biotechnology company that utilizes a “drug redevelopment” approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but often only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the same drug may not have sufficient time left for it to be commercially viable to developed it for the new indication. Marvel Biotech utilizes a non-traditional biotechnology model in that it has identified assets or compounds that have come off patent protection, and unlike a traditional redevelopment biotechnology model, develops synthetic chemical derivatives to significantly enhance certain compounds that results in a new novel and patentable asset. The business model result is that there is significantly less risk, cost and time to develop our assets compared to traditional biotechnology companies with the objective of developing or partnering the assets for commercialization.

Marvel Biotechnology Inc. has currently developed several new patented and patentable chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer’s, ADHD and addiction), cancer, and application to the non-neurological disease of non-alcoholic steatohepatitis liver fibrosis. Marvel Biotech is also exploring additional undisclosed targets to expand its asset pipeline.

Contact Information

For further information please contact:

J. Roderick (Rod) Matheson, CEO                            

Marvel Biosciences Corp.                                         

Email: info@MarvelBiotechnology.com                  

Phone: 403 770 2469

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Issuance of the Final TSXV Bulletin is subject to a number of conditions, including but not limited to TSXV acceptance and submission of conditional approval documents post-closing of the Transaction. 

Where applicable, the Transaction cannot close until the required TSXV approval is obtained.  There can be no assurance that the Transaction will be approved as proposed or at all.

Investors are cautioned that, except as disclosed in the TSXV Filing Statement (or other disclosure documents to be prepared by the Company) prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon.  Trading in the securities of an emerging junior company should be considered highly speculative.

The TSX Venture Exchange Inc. has in no way passed upon the merits of the Transaction and has neither approved nor disapproved the contents of this press release.

All information contained in this news release with respect to AVC and Marvel Biotech was supplied by the parties, respectively, for inclusion herein, and each parties’ directors and officers have relied on each other for any information concerning such party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Proposed Transaction and the future plans and objectives of the Company and Marvel Biotech are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and Marvel Biotech include the failure to obtain approval from the TSXV for the Transaction and other risks detailed from time to time in the filings made by the Company and Marvel Biotech under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company and Marvel Biotech. As a result, the Company and Marvel Biotech cannot guarantee that the Transaction will be approved on the terms and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company and Marvel Biotech will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.